High fibrinogen-to-albumin ratio powerful predictor of adverse outcomes in CAD patients

Patients with CAD history were from a prospective cohort which recruited 15,250 patients admitted to the First Affiliated Hospital of Xinjiang Medical University between December 2016 and October 2021.

Fourteen thousand nine hundred ninety-four patients enrolled were divided into two groups using ROC curve analysis. The primary endpoints were all-cause mortality (ACM) and cardiac mortality (CM), and secondary endpoints were major adverse cardiovascular events (MACEs), major adverse cardiac and cerebrovascular events (MACCEs), and non-fatal myocardial infarction (NFMI).

The study summary draws the following considerations:

• There were 10,076 participants in the low-FAR group and 4918 in the high-FAR group.
• Researchers compared the incidence of outcomes between the two groups.
• High-FAR group exhibited a higher incidence of ACM (5.3% vs 1.9%), CM (3.9% vs 1.4%), MACEs (9.8% vs 6.7%), MACCEs (10.4% vs 7.6%), and NFMI (2.3% vs 1.3%) when compared to the low-FAR group.
• The risk in the high-FAR group was increased by 2.182 fold in ACM, 2.116 fold in CM, 1.327 fold in MACEs, 1.280 fold in MACCEs and 1.791 fold in NFMI to the low-FAR group.

They concluded by saying, “High FAR group is an independent and powerful predictor of adverse outcomes in Coronary Artery Disease patients.”

Further reading:

https://link.springer.com/article/10.1007/s12265-023-10402-9